Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on February 28, 2024, covering events that occurred on February 27, 2024. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial performance data.
Material Changes
On February 27, 2024, the Company announced the pricing of an underwritten public offering. This event represents a material change in the company's capital structure, though specific terms such as the number of shares sold or the offering price are contained in the attached Pricing Press Release (Exhibit 99.1) and are not detailed in the body of this 8-K.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure that the information furnished in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Pricing Press Release) for the specific price per share and total capital raised in the underwritten public offering.
- Verify the number of shares issued and any underwriting discounts or commissions associated with the offering.
- Check subsequent filings (e.g., Form 4 or updated 10-Q/10-K) for the impact of this offering on the company's cash position and share count.